[go: up one dir, main page]

WO1999007728A3 - Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances - Google Patents

Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances Download PDF

Info

Publication number
WO1999007728A3
WO1999007728A3 PCT/FR1998/001757 FR9801757W WO9907728A3 WO 1999007728 A3 WO1999007728 A3 WO 1999007728A3 FR 9801757 W FR9801757 W FR 9801757W WO 9907728 A3 WO9907728 A3 WO 9907728A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
preparation
active substances
antibiotic
vectoring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR1998/001757
Other languages
French (fr)
Other versions
WO1999007728A2 (en
Inventor
Bernard Calas
Gerard Grassy
Alain Chavanieu
Michel Kaczorek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synt EM SA
Original Assignee
Synt EM SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synt EM SA filed Critical Synt EM SA
Priority to EP98941556A priority Critical patent/EP1003771A1/en
Priority to AU89889/98A priority patent/AU754617B2/en
Priority to IL13429398A priority patent/IL134293A0/en
Priority to CA002298932A priority patent/CA2298932A1/en
Priority to JP2000506230A priority patent/JP2001512739A/en
Publication of WO1999007728A2 publication Critical patent/WO1999007728A2/en
Publication of WO1999007728A3 publication Critical patent/WO1999007728A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention concerns peptides derived from antibiotic peptides or analogues thereof, characterised in that they are devoid of sulphide bond. The invention also concerns the use of these linear peptides for vectoring chemical substances and chemical compounds formed by said peptides coupled with at least an active substance. The invention further concerns the preparation of said peptides and compositions containing them.
PCT/FR1998/001757 1997-08-12 1998-08-06 Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances Ceased WO1999007728A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP98941556A EP1003771A1 (en) 1997-08-12 1998-08-06 Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances
AU89889/98A AU754617B2 (en) 1997-08-12 1998-08-06 Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances
IL13429398A IL134293A0 (en) 1997-08-12 1998-08-06 Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances
CA002298932A CA2298932A1 (en) 1997-08-12 1998-08-06 Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances
JP2000506230A JP2001512739A (en) 1997-08-12 1998-08-06 Linear peptides derived from antibiotic peptides, their preparation and their use in mediating active substances

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR97/10297 1997-08-12
FR9710297A FR2767323B1 (en) 1997-08-12 1997-08-12 LINEAR PEPTIDES DERIVED FROM ANTIBIOTIC PEPTIDES, THEIR PREPARATION AND THEIR USE FOR VECTORIZING ACTIVE SUBSTANCES

Publications (2)

Publication Number Publication Date
WO1999007728A2 WO1999007728A2 (en) 1999-02-18
WO1999007728A3 true WO1999007728A3 (en) 1999-06-24

Family

ID=9510249

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1998/001757 Ceased WO1999007728A2 (en) 1997-08-12 1998-08-06 Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances

Country Status (7)

Country Link
EP (1) EP1003771A1 (en)
JP (1) JP2001512739A (en)
AU (1) AU754617B2 (en)
CA (1) CA2298932A1 (en)
FR (1) FR2767323B1 (en)
IL (1) IL134293A0 (en)
WO (1) WO1999007728A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10023615B2 (en) 2008-12-22 2018-07-17 Xigen Inflammation Ltd. Efficient transport into white blood cells

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149095A0 (en) * 1998-11-11 2002-11-10 Pantheco As Conjugates between a peptide and a nucleic acid analog, such as pna, lna or a morpholino
DK173006B1 (en) * 1998-11-11 1999-11-01 Ke Burgmann As Method and plant for producing wall material for use in the manufacture of compensators, in particular for flue gas channels, as well as compensator material and compensator produced by the method
FR2786397B1 (en) * 1998-11-30 2003-01-10 Synt Em PEPTIDE VECTORS OF SUBSTANCES THROUGH THE HEMATOENCEPHALIC BARRIER FOR USE IN DIAGNOSIS OR THERAPY OF CNS DISEASE
FR2786398B1 (en) * 1998-11-30 2002-12-27 Synt Em ANTI-CANCER AND ANTI-CHEMORESISTANCE PHARMACEUTICAL COMPOSITION COMPRISING AN ANTI-CANCER AGENT AND AT LEAST ONE PEPTIDE
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
FR2810985B1 (en) * 2000-07-03 2004-12-24 Synt Em AMPHIPATHIC LINEAR PEPTIDES AND COMPOSITIONS CONTAINING THEM
GB0103110D0 (en) 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
WO2002031109A2 (en) 2000-10-13 2002-04-18 University Of Lausanne Intracellular delivery of biological effectors by novel transporter peptide sequences
US7033597B2 (en) * 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
FR2821272B1 (en) * 2001-02-23 2004-12-17 Synt Em COMPOUNDS CONSISTING OF AN ANALGESIC MOLECULE LINKED TO A VECTOR CAPABLE OF VECTORIZING THE SAME MOLECULATED THROUGH THE HEMATOENCEPHALIC BARRIER AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2829940A1 (en) * 2001-09-27 2003-03-28 Synt Em New composition, useful for treating central nervous system diseases, comprises an antibody linked to a linear peptide and is able to cross the blood-brain barrier
FR2830016B1 (en) * 2001-09-27 2004-06-25 Synt Em COMPOSITIONS FOR THE VECTORIZATION OF TAXOID DERIVATIVES THROUGH THE HEMATOENCEPHALIC BARRIER AND THEIR USE FOR THE TREATMENT OF CANCERS, PARTICULARLY BRAIN CANCERS
IL161069A0 (en) * 2001-10-16 2004-08-31 Synt Em Sa Use of peptide vectors to improve the immune response to antigens
FR2836474B1 (en) * 2002-02-22 2004-12-24 Synt Em COMPOUNDS, COMPOSITIONS AND METHOD FOR TRANSPORTING CYCLOSPORIN MOLECULES THROUGH THE HEMATOENCEPHALIC BARRIER
FR2840810B1 (en) * 2002-06-18 2005-02-11 Synt Em COMPOSITION FOR THE TRANSFER OF THERAPEUTIC MOLECULES TO LUNGS AND THEIR USE IN THE TREATMENT OF LUNG CANCERS AND PULMONARY DISEASES
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
FR2914928B1 (en) * 2007-04-12 2009-07-10 Univ Victor Segalen Bordeaux 2 PROCESS FOR PREPARING A CARRIER FOR IMMOBILIZATION OF A CELL, SUCH A CARRIER AND USES THEREOF
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009149560A1 (en) 2008-06-12 2009-12-17 Centre For Addiction And Mental Health Compositions and methods for modulating d1-d2 dopamine receptor interaction and function
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
JP5857056B2 (en) 2010-10-14 2016-02-10 ザイジェン インフラメーション エルティーディー Use of cell penetrating peptide inhibitors of the JNK signaling pathway to treat chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
US10624948B2 (en) 2013-06-26 2020-04-21 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004408A1 (en) * 1988-10-21 1990-05-03 Magainin Sciences, Inc. Composition and treatment with biologically active peptides and certain anions
WO1994018323A1 (en) * 1993-02-02 1994-08-18 Xoma Corporation Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same
WO1995016776A1 (en) * 1993-12-17 1995-06-22 Pioneer Hi-Bred International, Inc. Derivatives of tachyplesin having inhibitory activity towards plant pathogenic fungi
WO1996037508A1 (en) * 1995-05-26 1996-11-28 University Of California, Los Angeles Protegrins
WO1997018826A1 (en) * 1995-11-22 1997-05-29 Intrabiotics Pharmaceuticals, Inc. Fine tuned protegrins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013697A1 (en) * 1992-12-07 1994-06-23 Magainin Pharmaceuticals, Inc. Treatment of septic shock with conjugated biologically active peptides
US5756462A (en) * 1994-01-19 1998-05-26 Pfizer Inc. Pore forming peptides from Geolycosa riogrande
WO1996004001A1 (en) * 1994-08-05 1996-02-15 Molecular/Structural Biotechnologies, Inc. Site-specific biomolecular complexes
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
EP0861292B1 (en) * 1995-11-16 2000-06-07 Shell Internationale Researchmaatschappij B.V. Crosslinkable hydroxy functional polydiene polymer coating compostions and a process for preparing them

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004408A1 (en) * 1988-10-21 1990-05-03 Magainin Sciences, Inc. Composition and treatment with biologically active peptides and certain anions
WO1994018323A1 (en) * 1993-02-02 1994-08-18 Xoma Corporation Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same
WO1995016776A1 (en) * 1993-12-17 1995-06-22 Pioneer Hi-Bred International, Inc. Derivatives of tachyplesin having inhibitory activity towards plant pathogenic fungi
WO1996037508A1 (en) * 1995-05-26 1996-11-28 University Of California, Los Angeles Protegrins
WO1997018826A1 (en) * 1995-11-22 1997-05-29 Intrabiotics Pharmaceuticals, Inc. Fine tuned protegrins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MASUDA, MASAO ET AL: "A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12, Lys7]-polyphemusin II)", BIOCHEM. BIOPHYS. RES. COMMUN. (1992), 189(2), 845-50 CODEN: BBRCA9;ISSN: 0006-291X, 1992, XP002065781 *
QU, XIAO-DAN ET AL: "Protegrin structure and activity against Neisseria gonorrhoeae", INFECT. IMMUN. (1997), 65(2), 636-639 CODEN: INFIBR;ISSN: 0019-9567, 1997, XP002065780 *
TAMAMURA, HIROKAZU ET AL: "Antimicrobial activity and conformation of tachyplesin I and its analogs", CHEM. PHARM. BULL. (1993), 41(5), 978-80 CODEN: CPBTAL;ISSN: 0009-2363, 1993, XP002047195 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10023615B2 (en) 2008-12-22 2018-07-17 Xigen Inflammation Ltd. Efficient transport into white blood cells

Also Published As

Publication number Publication date
IL134293A0 (en) 2001-04-30
EP1003771A1 (en) 2000-05-31
FR2767323A1 (en) 1999-02-19
WO1999007728A2 (en) 1999-02-18
AU754617B2 (en) 2002-11-21
FR2767323B1 (en) 2001-01-05
CA2298932A1 (en) 1999-02-18
AU8988998A (en) 1999-03-01
JP2001512739A (en) 2001-08-28

Similar Documents

Publication Publication Date Title
WO1999007728A3 (en) Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances
IL142531A0 (en) Cyclic peptide compound, processes for the preparation thereof and pharmaceutical compositions containing the same
ZA979550B (en) Method for the preparation of methylidene malonate nanoparticles, nanoparticles which optionally contain one or more biologically active molecules, and pharmaceutical compositions containing them.
WO1998022136A3 (en) Stable lyophilized pharmaceutical substances from monoclonal or polyclonal antibodies
WO1998038984A3 (en) Formulations for hydrophobic pharmaceutical agents
TR200100366T2 (en) Compounds and compositions for dispensing the active substance.
IL136938A0 (en) 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THE PREPARATION THEREOF
GEP20104997B (en) Composition comprising anther2 antibodies
AU9592798A (en) Compositions containing an alpha1,2-fucose linkage and uses thereof
IL106600A (en) Peptides, pharmaceutical compositions containing the same and processes for the preparation thereof
IL137494A0 (en) Polypeptide compounds, process for the preparation thereof and pharmaceutical compositions containing the same
CA2355618A1 (en) Polyol/oil suspensions for the sustained release of proteins
AU1934495A (en) Formulations for il-11
AU8988098A (en) Vectors derived from antibodies for transferring substances into cells
CA2335551A1 (en) Thyroid hormone analogues and methods for their preparation
ZA974984B (en) New substituted thiazolidine-2,4-dione derivatives, processes for the obtaining thereof, and pharmaceutical compositions containing them.
AU3667399A (en) Monoclonal antibodies specific for anthrax spores and peptides derived from the antibodies thereof
CA2129755A1 (en) Stabilized radiopharmaceutical kits
EP1140097A4 (en) Products comprising trihydroxystilbenes and derivatives thereof and methods for their manufacture and use
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
WO2000076528A3 (en) Pharmaceutical preparation containing proteins
HUP0001093A3 (en) Oxazolidines as 5-ht2a-antagonists, pharmaceutical compositions containing the same and process for their preparation
IL140414A0 (en) Beta lactam compounds, processes for the preparation thereof and pharmaceutical compositions containing the same
HUP9702480A3 (en) New polymorphous form of doxazosin-mesylate (form. i.), process for it's preparation and pharmaceutical compositions containing the same
AU5069298A (en) Novel triterpene glycoside compound, process for preparation thereof and anti-cancer composition containing the same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 134293

Country of ref document: IL

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2298932

Country of ref document: CA

Ref country code: CA

Ref document number: 2298932

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 89889/98

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998941556

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998941556

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09485571

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 89889/98

Country of ref document: AU